Gian Paolo Caviglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2648305/publications.pdf

Version: 2024-02-01

201658 276858 2,404 131 27 41 citations g-index h-index papers 132 132 132 3041 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. Journal of Hepatology, 2018, 69, 301-307.	3.7	126
2	Outcome of chronic delta hepatitis in Italy: A long-term cohort study. Journal of Hepatology, 2010, 53, 834-840.	3.7	122
3	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	12.1	113
4	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	3.7	100
5	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology, 2016, 63, 107-116.	7.3	67
6	Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Medica, 2019, 110, 95-100.	0.9	66
7	Physiopathology of intestinal barrier and the role of zonulin. Minerva Biotecnologica, 2019, 31, .	1.2	66
8	Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scandinavian Journal of Gastroenterology, 2014, 49, 1419-1424.	1.5	54
9	Liver fibrosis: the 2017 state of art. Panminerva Medica, 2017, 59, 320-331.	0.8	53
10	Highly sensitive alphaâ€fetoprotein, <i>Lens culinaris</i> agglutininâ€feactive fraction of alphaâ€fetoprotein and desâ€gammaâ€carboxyprothrombin for hepatocellular carcinoma detection. Hepatology Research, 2016, 46, E130-5.	3.4	52
11	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. Journal of Clinical Medicine, 2019, 8, 1646.	2.4	50
12	Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. World Journal of Gastroenterology, 2016, 22, 8187.	3.3	49
13	Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scandinavian Journal of Gastroenterology, 2019, 54, 407-413.	1.5	46
14	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites, 2021, 11, 155.	2.9	44
15	Fecal calprotectin: beyond intestinal organic diseases. Panminerva Medica, 2018, 60, 29-34.	0.8	41
16	Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scandinavian Journal of Gastroenterology, 2015, 50, 1376-1381.	1.5	35
17	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Medica, 2017, 59, 283-289.	0.8	35
18	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scandinavian Journal of Gastroenterology, 2018, 53, 734-740.	1.5	34

#	Article	IF	CITATIONS
19	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 3941.	2.4	34
20	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. Minerva Biotecnologica, 2020, 32, .	1.2	33
21	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32
22	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. Therapeutic Drug Monitoring, 2012, 34, 722-728.	2.0	31
23	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. Journal of Molecular Medicine, 2020, 98, 595-612.	3.9	31
24	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 311-317.e1.	4.4	30
25	Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners. Angle Orthodontist, 2017, 87, 74-81.	2.4	30
26	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 800.	2.4	29
27	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Research, 2013, 100, 114-119.	4.1	27
28	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers, 2020, 12, 3218.	3.7	27
29	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clinical Gastroenterology and Hepatology, 2021, 19, 46-60.e8.	4.4	27
30	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. Frontiers in Endocrinology, 2021, 12, 716533.	3.5	27
31	Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn�s disease: an observational study. Revista Espanola De Enfermedades Digestivas, 2020, 112, 195-200.	0.3	26
32	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. Cancer Biomarkers, 2018, 21, 603-612.	1.7	24
33	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers, 2021, 13, 2305.	3.7	24
34	Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnologica, 2019, 31, .	1.2	24
35	Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. Journal of Clinical Virology, 2014, 60, 341-346.	3.1	22
36	Usefulness of the index of <scp>NASH</scp> – <scp>ION</scp> for the diagnosis of steatohepatitis in patients with nonâ€alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	3.9	22

#	Article	IF	CITATIONS
37	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. International Journal of Molecular Sciences, 2020, 21, 8838.	4.1	22
38	Noninvasive assessment of liver fibrosis: key messages for clinicians. Polish Archives of Internal Medicine, 2014, 124, 329-335.	0.4	22
39	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Medica, 2019, 110, 401-409.	0.9	22
40	Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. Oral Diseases, 2022, 28, 1029-1041.	3.0	21
41	Hepatitis B coreâ€related antigen kinetics in chronic hepatitis B virus genotype Dâ€infected patients treated with nucleos(t)ide analogues or pegylatedâ€interferonâ€î±. Hepatology Research, 2017, 47, 747-754.	3.4	20
42	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 1323.	2.4	20
43	<i>IL28B</i> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World Journal of Gastroenterology, 2014, 20, 13146.	3.3	20
44	Chronic hepatitis <scp>C</scp> virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and <scp>B</scp> â€cell nonâ€ <scp>H</scp> odgkin lymphoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 742-747.	2.8	19
45	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Digestive and Liver Disease, 2016, 48, 55-61.	0.9	19
46	The medical impact of hepatitis D virus infection in Uzbekistan. Liver International, 2019, 39, 2077-2081.	3.9	19
47	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. Journal of Clinical Medicine, 2020, 9, 2353.	2.4	18
48	Treatment of hepatitis D: an unmet medical need. Clinical Microbiology and Infection, 2020, 26, 824-827.	6.0	18
49	Incremental value of HBcrAg to classify 1582 HBeAgâ€negative individuals in chronic infection without liver disease or hepatitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 733-744.	3.7	18
50	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. Minerva Medica, 2017, 108, 489-495.	0.9	17
51	The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scandinavian Journal of Gastroenterology, 2018, 53, 141-146.	1.5	16
52	Risk of drug interactions and prescription appropriateness in elderly patients. Irish Journal of Medical Science, 2020, 189, 953-959.	1.5	16
53	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. Journal of Clinical Medicine, 2021, 10, 3387.	2.4	16
54	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. Journal of Advanced Research, 2021, 33, 183-187.	9.5	16

#	Article	IF	Citations
55	Faecal miRNA profiles associated with age, sex, BMI, and lifestyle habits in healthy individuals. Scientific Reports, 2021, 11, 20645.	3.3	16
56	Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers, 2022, 14, 828.	3.7	15
57	Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. Digestive and Liver Disease, 2014, 46, 1020-1024.	0.9	14
58	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers, 2020, 12, 2776.	3.7	14
59	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114985.	1.8	14
60	Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. Minerva Biotecnologica, 2018, 30, .	1.2	13
61	DAT1 VNTR Polymorphisms in a European and an African Population: Identification of a New Allele. Human Biology, 2008, 80, 191-198.	0.2	12
62	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Annals of Hepatology, 2014, 13, 91-97.	1.5	12
63	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Antiviral Research, 2014, 109, 7-14.	4.1	12
64	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Lithuania), 2019, 55, 441.	2.0	12
65	Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. RMD Open, 2021, 7, e001755.	3.8	12
66	Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test. Minerva Biotecnologica, 2019, 31, .	1.2	12
67	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Digestive and Liver Disease, 2022, 54, 1101-1108.	0.9	12
68	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 635.	2.4	12
69	Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Biochemia Medica, 2016, 26, 114-120.	2.7	11
70	HLAâ€DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 39-44.	1.8	11
71	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. Medicina (Lithuania), 2020, 56, 285.	2.0	11
72	Management of Helicobacter pylori in Piedmont, Italy. Minerva Gastroenterologica E Dietologica, 2018, 64, 235-250.	2.2	11

#	Article	IF	CITATIONS
73	Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Current Oncology, 2022, 29, 1422-1429.	2.2	11
74	Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy. Hepatitis Monthly, 2012, 12, e7292.	0.2	9
75	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 1289-1292.	0.4	9
76	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, .	0.5	9
77	Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics, 2021, 11, 187.	2.6	9
78	Inflammatory Bowel Disease Nurseâ€"Practical Messages. Nursing Reports, 2021, 11, 229-241.	2.1	8
79	Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 4961.	2.4	8
80	Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without Helicobacter pylori infection. Minerva Biotechnology and Biomolecular Research, 2017, 29, .	0.5	7
81	Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. Minerva Biotecnologica, 2019, 31, .	1.2	7
82	Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. Scandinavian Journal of Gastroenterology, 2019, 54, 1339-1345.	1.5	6
83	Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 1818.	4.1	6
84	Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. Journal of Clinical Medicine, 2021, 10, 3308.	2.4	6
85	Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA. Clinical Laboratory, 2018, 64, 411-412.	0.5	6
86	Basic and clinical aspects of resistin. Minerva Biotecnologica, 2018, 30, .	1.2	5
87	Detection of gastrointestinal cancer: the role of cancer biomarkers. Minerva Biotecnologica, 2019, 31,	1.2	5
88	Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. Clinical Laboratory, 2020, 66, .	0.5	5
89	Strategies for i>Helicobacter pylori i>eradication in the year 2020. Saudi Journal of Gastroenterology, 2020, 26, 63.	1.1	5
90	Re: El-Garem etÂal.: Seminal Helicobacter pylori Treatment Improves Sperm Motility in Infertile Asthenozoospermic Men (Urology 2014;84:1347-1350). Urology, 2015, 85, 1217.	1.0	4

#	Article	IF	Citations
91	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. Journal of Hepatology, 2019, 70, 793-795.	3.7	4
92	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology, 2021, 10, 215.	2.8	4
93	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals, 2021, 14, 1230.	3.8	4
94	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. Biomedicines, 2022, 10, 792.	3.2	4
95	Role of serum hepatitis B core-related antigen in chronic hepatitis B infection. Minerva Biotechnology and Biomolecular Research, 2017, 30, .	0.5	3
96	Role and function of exosomal miR-9-3p in hepatocellular carcinoma. Minerva Medica, 2017, 109, 4-6.	0.9	3
97	Targeting ILâ€10, ZOâ€1 gene expression and ILâ€6/STATâ€3 transâ€signalling by a combination of atorvastatin mesalazine to enhance antiâ€inflammatory effects and attenuate progression of oxazoloneâ€induced colitis. Fundamental and Clinical Pharmacology, 2021, 35, 141-142.	and 1.9	3
98	Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. Minerva Gastroenterologica E Dietologica, 2019, 65, 77-78.	2.2	3
99	Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitisâ€)?. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 307.	1.0	3
100	Helicobacter pylori, gastric cancer and gastric cancer stem cells. Minerva Biotechnology and Biomolecular Research, 2017, 29, .	0.5	3
101	Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases. Gastroenterology Insights, 2021, 12, 443-445.	1.2	3
102	On "Diagnostic value of aberrant gene methylation in stool samples for colorectal cancer or adenomas". Panminerva Medica, 2016, 58, 102.	0.8	3
103	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, 196-208.	0.5	3
104	Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification. Minerva Gastroenterology, 2022, 68, .	0.5	2
105	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 3257.	2.4	2
106	Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction. Hepatitis Monthly, 2015, 15, e30853.	0.2	2
107	Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics, 2021, 11, 2185.	2.6	2
108	Reply to: diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. Scandinavian Journal of Gastroenterology, 2015, 50, 623-624.	1.5	1

#	Article	IF	CITATIONS
109	Hepatitis B core-related antigen: a novel biomarker for chronic hepatitis B treatment. Minerva Gastroenterology, 2017, 63, 169-171.	0.5	1
110	THU-208-Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. Journal of Hepatology, 2019, 70, e254-e255.	3.7	1
111	Hepatitis D virus in Uzbekistan. The Lancet Gastroenterology and Hepatology, 2020, 5, 238-240.	8.1	1
112	Tight junction regulation in celiac disease: role of larazotide acetate. Minerva Gastroenterology, 2021, , .	0.5	1
113	A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. Life, 2021, 11, 650.	2.4	1
114	Comment on "Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study― Turkish Journal of Gastroenterology, 2018, 29, 719-719.	1.1	1
115	Fecal calprotectin: a biomarker for intestinal inflammation. Inflammation and Cell Signaling, 0, , .	1.6	1
116	Edaravone and MAPK pathway: the key role of gut permeability. Minerva Medica, 2020, 111, 181.	0.9	1
117	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Annals of Hepatology, 2013, 13, 91-7.	1.5	1
118	Utilizzo del test per la quantificazione dell'M2-PK fecale nell'ambito di un programma di screening per il carcinoma colorettale in soggetti positivi al FIT. Rivista Italiana Della Medicina Di Laboratorio, 2016, 12, 119-121.	0.4	0
119	Considerations about alcohol abstinence and liver disease. Minerva Psychiatry, 2018, 59, .	0.3	o
120	Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition― Journal of Hepatology, 2019, 70, 559-560.	3.7	0
121	Seronegative occult hepatitis C virus infection: what is its clinical relevance?. Minerva Biotecnologica, 2021, 32, .	1.2	O
122	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101611.	1.5	0
123	Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. Minerva Gastroenterology, 2021, , .	0.5	0
124	Is the pattern of liver disease etiology changing in China?. Minerva Medica, 2021, 112, 521.	0.9	0
125	Chronic HCV infection and lymphoproliferative disorders: association or causal relationship?. Abdomen, 0, , .	0.0	0
126	Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine. İstanbul Medical Journal, 2017, 18, 189-195.	0.1	0

#	Article	IF	CITATIONS
127	Role of immunoglobulin indexes in patients with chronic hepatitis B. Minerva Medica, 2020, 111, 382-383.	0.9	O
128	Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II). Minerva Medica, 2022, 113, 106-108.	0.9	0
129	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq1 1 0.78	4314 rgBT	Overlock
130	A Comment on the Letter. Archives of Iranian Medicine, 2016, 19, 886.	0.6	0
131	Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice― Journal of Clinical Medicine, 2022, 11, 2797.	2.4	O